. Author manuscript; available in PMC: 2009 Jan 6.

Published in final edited form as: Cancer. 2008 Apr 1;112(7):1522–1528. doi: 10.1002/cncr.23336

TABLE 4.

Incidence of Lenalidomide Associated Thrombosis in Recent Clinical Trials

Study	Regimen	Disease status	No. of patients	Rate of deep vein thrombosis	Thromboprophylaxis
Weber, 2006²⁷	Lenalidomide 25 mg Days 1–21 every 28 d plus dexamethasone 40 mg Days 1–4, 9–12, 17–20 every 28 d	Relapsed, refractory	177	15%	None
Zonder, 2005²⁵	Lenalidomide 25 mg Days 1–28 every 35 d plus dexamethasone 40 mg Days 1–4, 9–12, 17–20 every 35 d	Newly diagnosed	38	75%; reduced to 19% after institution of aspirin prophylaxis	ASA in the second phase
Richardson, 2006²⁸	Lenalidomide 30 mg daily (or15 mg twice a d) administered on Days 1–21 every 28 dd with or without dexamethasone Days 1–4, 15–18 every 28 d	Relapsed, refractory	102	3% (rate is 4.4% among the 68 patients who received lenalidomide plus dexamethasone	None
Rajkumar, 2007²⁶	Lenalidomide 25 mg Days 1–21 every 28 d plus dexamethasone 40 mg Days 1–4, 9–12, 17–20 every 28 d	Newly diagnosed	223	22.1%	ASA (randomized between coumadin and ASA in the expansion phase)
Rajkumar, 2007²⁶	Lenalidomide 25 mg Days 1–21 every 28 d plus dexamethasone 40 mg Days 1, 8, 15, 22 every 28 d	Relapsed, refractory	222	6.1%	ASA

ASA indicates aspirin; High dose dex, dexamethasone 40 mg (Days 1–4, 9–12 and 17–20 in a 28 d cycle).